MRI and PET/MRI in Hematology and Oncology
Accurate staging and precise measurement of tumor burden are essential to plan effective therapy of cancer patients. Evaluation of therapeutic changes is equally essential to modify the therapeutic strategy. FDG-PET /CT has become a cornerstone in the staging and restaging of neoplasms, in the evaluation of therapeutic efficacy during or after treatment and in the planning of radiotherapy, proving to be more sensitive than contrast-enhanced CT in the staging of lymphoma and in the diagnosis of diffuse neoplasms.
To date, MRI has been considered only an alternative method for the diagnosis and staging of various hematologic and oncologic diseases especially in younger patients, due to the absence of ionizing radiation, high soft tissue contrast and good spatial resolution. The use of advanced sequences, such as DWI, however, has further improved the diagnostic accuracy of MRI in oncology. The recently developed whole body (WB) MRI technique has significantly increased the diagnostic accuracy of MRI in onco-hematological imaging, providing an excellent total body imaging.
In myeloma only WB-MRI is now recognized as a highly sensitive test for diagnosis and staging. Instead in lymphoma, WB-DWI-MRI merely serves as an alternative technique to FDG-PET/CT, especially in pediatric patients, although its use is increasingly important in adult patients as well. Despite the high sensitivity in the diagnosis and follow up of lymphomas and non-hematologic malignancies, WB DWI MRI is not recommended in current guidelines yet.
PET/MRI is a relatively new hybrid imaging technique, recently introduced into routine clinical practice. Several comparative studies between hybrid PET/CT and PET/MRI imaging techniques recently been performed in relatively small patient populations have provided preliminary satisfactory results in favour of MRI.
The aim of this issue is to discuss the current clinical applications of the up-to-date MRI techniques in oncology and hematology as well as to propose research topics in the field of hematology and oncology.
Prof. Dr. Francesca Maccioni
Prof. Dr. Leonardo Pace
• Whole Body MRI
• Diffusion Weighted Imaging
• CNS tumor
• Head & neck tumor
• Liver cancer
• Gynecological cancer
• Musculoskeletal tumor
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|5.2||7.4||2009||18.2 Days||CHF 2900|
|3.6||3.6||2011||18.8 Days||CHF 2600|
|-||-||2020||20.1 Days||CHF 1000|
Journal of Clinical Medicinejcm
|3.9||5.4||2012||19.7 Days||CHF 2600|
|1.9||2.3||2015||23.5 Days||CHF 2400|
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.
Published Papers (9 papers)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: FDG-PET/MRI in Differentiate Thyroid Cancer
Authors: Michele Klain1; Carmela Nappi1; Emanuele Nicolai2; Rosj Galicchio3; Valeria Romeo1; Cavaliere Carlo2; Leandra Piscopo1; Teresa Pellegrino3; Fabio Volpe1; Giovanni Storto3; Marco Salvatore2; Alberto Cuocolo1; Leonardo Pace4
Affiliation: 1 Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II, Napoli;
2 IRCCS-SDN, Napoli;
3 Medicina Nucleare, IRCCS-CROB, Rionero in Vulture
4 Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitan
Abstract: We investigated the prognostic power of PET/MRI in differentiated thyroid cancer. All patients included in the study underwent FDG-PET/MRI within follow-up after radionuclide iodine-131 therapy to detect recurrence. PET and MRI variables were considered either separate or combined. Survival analysis was performed by univariate Cox proportional hazard regression analysis and event-free survival curves were obtained by Kaplan-Meier method and compared with the log-rank test. Our results showed that among all variables included in the analysis, including those derived from imaging as well as the clinical and haematological ones, serum thyroglobulin and positive FDG-PET/MR are predictors of thyroid cancer recurrence.
Title: PSMA PET/MR vs PET/CT: impact on lesion detection, interpretation and clinical management
Authors: Bendik Skarre Abrahamsen; Mattijs Elschot
Affiliation: Department of Circulation and Medical Imaging, NTNU—Norwegian University of Science and Technology, 7030 Trondheim, Norway
Abstract: Not available